(COLL) Collegium Pharmaceutical - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.026m USD | Total Return: 19% in 12m

Pain Medication, ADHD Medication, Constipation Treatment
Total Rating 42
Safety 76
Buy Signal -0.50
Drug Manufacturers - Specialty & Generic
Industry Rotation: +5.8
Market Cap: 1.03B
Avg Turnover: 18.4M USD
ATR: 4.25%
Peers RS (IBD): 26.5
Risk 5d forecast
Volatility38.1%
Rel. Tail Risk-5.10%
Reward TTM
Sharpe Ratio0.38
Alpha-4.42
Character TTM
Beta0.637
Beta Downside0.749
Drawdowns 3y
Max DD41.07%
CAGR/Max DD0.28
EPS (Earnings per Share) EPS (Earnings per Share) of COLL over the last years for every Quarter: "2021-03": 0.41, "2021-06": 0.27, "2021-09": 0.22, "2021-12": -0.51, "2022-03": 0.44, "2022-06": 0.32, "2022-09": 0.01, "2022-12": -0.21, "2023-03": -0.51, "2023-06": 0.34, "2023-09": 0.53, "2023-12": 0.82, "2024-03": 1.45, "2024-06": 1.62, "2024-09": 1.61, "2024-12": 1.77, "2025-03": 1.49, "2025-06": 1.68, "2025-09": 2.25, "2025-12": 2.04, "2026-03": 0,
EPS CAGR: -10.46%
EPS Trend: 64.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of COLL over the last years for every Quarter: 2021-03: 87.721, 2021-06: 82.942, 2021-09: 78.843, 2021-12: 27.362, 2022-03: 83.751, 2022-06: 123.549, 2022-09: 127.013, 2022-12: 129.62, 2023-03: 144.767, 2023-06: 135.546, 2023-09: 136.709, 2023-12: 149.745, 2024-03: 144.923, 2024-06: 145.276, 2024-09: 159.301, 2024-12: 181.949, 2025-03: 177.757, 2025-06: 188, 2025-09: 209.361, 2025-12: 205.449, 2026-03: null,
Rev. CAGR: 27.04%
Rev. Trend: 91.4%
Last SUE: -0.14
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: COLL Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. (COLL) is a specialty pharmaceutical company focused on pain management. The company develops and commercializes prescription medicines.

Its product portfolio includes treatments for attention deficit hyperactivity disorder (Jornay PM), severe pain (Belbuca, Xtampza ER, Nucynta ER/IR), and opioid-induced constipation (Symproic). The pharmaceutical sector is characterized by high research and development costs and extensive regulatory approval processes.

COLL operates a business model common in specialty pharmaceuticals, focusing on niche markets with specific medical needs. Further research on ValueRay can provide deeper insights into COLLs financial performance and market position.

Headlines to Watch Out For
  • Xtampza ER sales growth drives opioid pain management revenue
  • Jornay PM adoption expands ADHD treatment market share
  • Belbuca prescription volume impacts chronic pain revenue
  • Nucynta franchise sales contribute to pain portfolio
  • Regulatory scrutiny on opioid products creates market risk
Piotroski VR‑10 (Strict) 7.0
Net Income: 62.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA 7.55 > 1.0
NWC/Revenue: 32.21% < 20% (prev -4.32%; Δ 36.52% < -1%)
CFO/TA 0.20 > 3% & CFO 329.3m > Net Income 62.9m
Net Debt (689.5m) to EBITDA (599.8m): 1.15 < 3
Current Ratio: 1.57 > 1.5 & < 3
Outstanding Shares: last quarter (39.7m) vs 12m ago -1.02% < -2%
Gross Margin: 59.35% > 18% (prev 0.60%; Δ 5.88k% > 0.5%)
Asset Turnover: 47.02% > 50% (prev 37.96%; Δ 9.06% > 0%)
Interest Coverage Ratio: 1.55 > 6 (EBITDA TTM 599.8m / Interest Expense TTM 167.8m)
Altman Z'' 1.77
A: 0.15 (Total Current Assets 691.4m - Total Current Liabilities 440.0m) / Total Assets 1.66b
B: -0.06 (Retained Earnings -101.1m / Total Assets 1.66b)
C: 0.16 (EBIT TTM 260.4m / Avg Total Assets 1.66b)
D: -0.07 (Book Value of Equity -100.8m / Total Liabilities 1.36b)
Altman-Z'' Score: 1.77 = BBB
Beneish M -3.33
DSRI: 0.75 (Receivables 211.3m/228.5m, Revenue 780.6m/631.4m)
GMI: 1.01 (GM 59.35% / 59.76%)
AQI: 0.82 (AQ_t 0.57 / AQ_t-1 0.70)
SGI: 1.24 (Revenue 780.6m / 631.4m)
TATA: -0.16 (NI 62.9m - CFO 329.3m) / TA 1.66b)
Beneish M-Score: -3.33 (Cap -4..+1) = AA
What is the price of COLL shares? As of April 07, 2026, the stock is trading at USD 32.59 with a total of 344,971 shares traded.
Over the past week, the price has changed by +1.88%, over one month by -12.60%, over three months by -29.47% and over the past year by +19.03%.
Is COLL a buy, sell or hold? Collegium Pharmaceutical has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy COLL.
  • StrongBuy: 2
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the COLL price?
Analysts Target Price 54.2 66.2%
Collegium Pharmaceutical (COLL) - Fundamental Data Overview as of 05 April 2026
P/E Trailing = 18.6763
P/E Forward = 4.415
P/S = 1.3144
P/B = 3.4998
Revenue TTM = 780.6m USD
EBIT TTM = 260.4m USD
EBITDA TTM = 599.8m USD
Long Term Debt = 780.3m USD (from longTermDebt, last quarter)
Short Term Debt = 30.4m USD (from shortTermDebt, last quarter)
Debt = 940.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 689.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.56b USD (1.03b + Debt 940.6m - CCE 406.5m)
Interest Coverage Ratio = 1.55 (Ebit TTM 260.4m / Interest Expense TTM 167.8m)
EV/FCF = 4.76x (Enterprise Value 1.56b / FCF TTM 327.6m)
FCF Yield = 21.00% (FCF TTM 327.6m / Enterprise Value 1.56b)
FCF Margin = 41.97% (FCF TTM 327.6m / Revenue TTM 780.6m)
Net Margin = 8.05% (Net Income TTM 62.9m / Revenue TTM 780.6m)
Gross Margin = 59.35% ((Revenue TTM 780.6m - Cost of Revenue TTM 317.3m) / Revenue TTM)
Gross Margin QoQ = 62.49% (prev 61.70%)
Tobins Q-Ratio = 0.94 (Enterprise Value 1.56b / Total Assets 1.66b)
Interest Expense / Debt = 11.14% (Interest Expense 104.8m / Debt 940.6m)
Taxrate = 41.58% (12.1m / 29.0m)
NOPAT = 152.1m (EBIT 260.4m * (1 - 41.58%))
Current Ratio = 1.57 (Total Current Assets 691.4m / Total Current Liabilities 440.0m)
Debt / Equity = 3.12 (Debt 940.6m / totalStockholderEquity, last quarter 301.7m)
Debt / EBITDA = 1.15 (Net Debt 689.5m / EBITDA 599.8m)
Debt / FCF = 2.10 (Net Debt 689.5m / FCF TTM 327.6m)
Total Stockholder Equity = 260.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.79% (Net Income 62.9m / Total Assets 1.66b)
RoE = 24.11% (Net Income TTM 62.9m / Total Stockholder Equity 260.8m)
RoCE = 25.02% (EBIT 260.4m / Capital Employed (Equity 260.8m + L.T.Debt 780.3m))
RoIC = 14.08% (NOPAT 152.1m / Invested Capital 1.08b)
WACC = 7.41% (E(1.03b)/V(1.97b) * Re(8.24%) + D(940.6m)/V(1.97b) * Rd(11.14%) * (1-Tc(0.42)))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.41%
[DCF] Terminal Value 83.54% ; FCFF base≈277.9m ; Y1≈342.8m ; Y5≈584.9m
[DCF] Fair Price = 338.3 (EV 11.43b - Net Debt 689.5m = Equity 10.74b / Shares 31.8m; r=7.41% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.44 | EPS CAGR: -10.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.42 | Revenue CAGR: 27.04% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.75 | Chg7d=-0.074 | Chg30d=-0.054 | Revisions Net=-2 | Analysts=5
EPS current Year (2026-12-31): EPS=7.29 | Chg7d=-0.166 | Chg30d=-0.640 | Revisions Net=-3 | Growth EPS=-1.7% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=6.39 | Chg7d=+0.291 | Chg30d=+0.274 | Revisions Net=+0 | Growth EPS=-12.4% | Growth Revenue=-6.4%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 8.2% - Earnings Yield 5.4%)
[Growth] Growth Spread = +2.1% (Analyst 5.0% - Implied 2.9%)
External Resources
Dataroma Stockcircle